Sepsis in the ICU: who needs progress?

作者信息

Vincent Jean-Louis

出版信息

Intensive Care Med. 2006 Apr;32(4):609; author reply 610-2. doi: 10.1007/s00134-006-0089-6. Epub 2006 Mar 1.

DOI:10.1007/s00134-006-0089-6

PMID:16508754

Abstract

摘要

相似文献

Sepsis in the ICU: who needs progress?

Intensive Care Med. 2006 Apr;32(4):609; author reply 610-2. doi: 10.1007/s00134-006-0089-6. Epub 2006 Mar 1.

Do-not-resuscitate orders in intensive care units. Current practices and recent changes.

JAMA. 1993 Nov 10;270(18):2213-7.

Does sepsis treatment differ between primary and overflow intensive care units?

J Hosp Med. 2012 Oct;7(8):600-5. doi: 10.1002/jhm.1955. Epub 2012 Aug 3.

Intensive insulin therapy in the ICU: benefit versus harm?

Intensive Care Med. 2007 Jul;33(7):1302. doi: 10.1007/s00134-007-0648-5. Epub 2007 Apr 26.

The impact of DNR orders on nursing workload in an ICU.

Am J Crit Care. 1998 May;7(3):248-9.

Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study.

J Antimicrob Chemother. 2008 Feb;61(2):436-41. doi: 10.1093/jac/dkm460. Epub 2007 Dec 3.

Management of sepsis in the ICU.

Int Anesthesiol Clin. 2009 Winter;47(1):55-66. doi: 10.1097/AIA.0b013e318194ffb6.

First sepsis drug nears market.

Nat Med. 2001 May;7(5):516-7. doi: 10.1038/87809.

Economic implications of the timing of do-not-resuscitate orders for ICU patients.

New Horiz. 1997 Feb;5(1):51-5.

Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.

Croat Med J. 2006 Jun;47(3):385-97.

引用本文的文献

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.

BMC Anesthesiol. 2007 Jun 25;7:5. doi: 10.1186/1471-2253-7-5.

The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia.

Intensive Care Med. 2007 Jun;33(6):1085-93. doi: 10.1007/s00134-007-0631-1. Epub 2007 Apr 25.

本文引用的文献

The patents-based pharmaceutical development process: rationale, problems, and potential reforms.

JAMA. 2005 Oct 26;294(16):2075-82. doi: 10.1001/jama.294.16.2075.

Activated protein C: do more survive?

Intensive Care Med. 2005 Dec;31(12):1624-6. doi: 10.1007/s00134-005-2829-4. Epub 2005 Oct 15.

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Crit Care Med. 2005 Oct;33(10):2266-77. doi: 10.1097/01.ccm.0000181729.46010.83.

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

Crit Care. 2005;9 Suppl 4(Suppl 4):S38-45. doi: 10.1186/cc3747. Epub 2005 Aug 25.

Efficacy and safety of recombinant human activated protein C for severe sepsis.

N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验